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Survival After
Liver Transplantation
for Familial
Transthyretin AmyloidosisFamilial transthyretin amyloidosis (ATTR) is a rare,
life-threatening, autosomal dominant disease in-
volving mainly the heart and the peripheral nervous
system due to a point mutation of the transthyretin
(TTR) gene. By removing the main source of the
mutated TTR, liver transplantation (LT) has become
the standard treatment for ATTR (1). Because the
demand for liver grafts exceeds the number of avail-
able organs and because new treatments have
recently emerged, screening patients at high risk of
death after LT is critical (2).
We identiﬁed 215 consecutive patients who un-
derwent LT between 1993 and 2011. The diagnosis
was made by the observation of both amyloid
deposits in biopsy specimens and a TTR mutation.
The pre-operative evaluation included physical ex-
amination, electrocardiography, echocardiography,
autonomic dysfunction score, and polyneuropathy
disability score (PND) calculation. The primary
study endpoint was all-cause mortality after LT. Theprognostic model predicting the individual probabil-
ity of death within the ﬁrst 5 years after LT was
developed from the Cox proportional hazards model
and was internally validated using bootstrapping.
At the time of LT, patients’median age was 43 years,
61% were men, and 69% carried the Val30Met
mutation. There were 81% patients in New York Heart
Association (NYHA) functional class I, 40% had con-
duction disorders, 36% had a $12-mm interventricular
septum on the echocardiograms, and the median left
ventricular ejection fraction was 65%. All patients
presented with neurological manifestations of ATTR:
isolated sensory disturbances (PND I: 61%), difﬁculties
with walking (PND II: 22%), and the need for cane(s)
to walk (PND III: 17%). The vegetative score was ab-
normal in 82%, and 59% had orthostatic hypotension.
Over a median follow-up of 5.9 years after LT, 84
patients died, and cardiac events were the leading
cause of death (38% of all deaths). The signiﬁcant
pejorative factors were PND score $III (hazard ratio
[HR]: 1.75; 95% conﬁdence interval [CI]: 1.04 to 2.96;
p ¼ 0.036), orthostatic hypotension (HR: 2.26; 95%
CI: 1.39 to 4.22; p ¼ 0.001), NYHA functional class >I
(HR: 2.25; 95% CI: 1.18 to 4.27; p ¼ 0.014), QRS
duration $120 ms (HR: 1.90; 95% CI: 1.05 to 3.43;
p¼ 0.035), thickened interventricular septum (for each
millimeter: HR: 1.12; 95% CI: 1.04 to 1.20; p ¼ 0.002).
The individual probability of death at 5 years was
calculated as Pdeath at 5 years ¼ 1  0.735e(coeff sum  1.27810),
where coeff sum ¼ (0.57423  PND score $III) þ
(0.77339  orthostatic hypotension) þ (0.91192 
NYHA functional class >I) þ (0.60378  QRS $120
ms) þ (0.14589  [interventricular septum thickness
 6]). Risk can be computed using the online
calculator. The calibration slope was 0.89 (95% CI:
0.64 to 1.15), the C-index of Harrel was 0.68 (95% CI:
0.45 to 0.88), and the concordance probability esti-
mate was 0.71 (95% CI: 0.67 to 0.75). The area under
the receiver-operating characteristic curve for the
5-year survival was 0.80, and signiﬁcant differences
of survival were found according to the 5-year
death risk (Figure 1). Pre-operative identiﬁcation of a
high-risk proﬁle (risk >50%) was retrospectively
documented in 40 of 215 patients (19%).
The risk score was built from variables that
measured the cardiac and neurological status
regardless of mutation type. Therefore, our proposed
score should be useful to gauge the risk of patients
with rare variants of TTR and to take into account the
phenotypic variability encountered among patients
with a similar mutation. The study population was
representative of a region where ATTR is not endemic
and the 74% 5-year survival of our patients in line
with the 77% previously reported (3). Previous reports
FIGURE 1 Survival of ATTR Patients After Liver Transplantation According to the Risk Score
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Survival of ATTR patients after liver transplantation differs signiﬁcantly according to the score (log-rank test: p < 0.0001). For high-risk
patients (score <50%), the 1-year survival rate was 70% and the 5-year survival rate was 31%. ATTR ¼ transthyretin amyloidosis.
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2155suggested that septum thickness could be associated
with a worse prognosis in ATTR patients with a liver
transplant (4). Wide QRS complexes on electrocardi-
ography were associated with an independent
increased risk of death in our study, and this was
consistent with the high frequency of conduction
disorders in transthyretin cardiac amyloidosis.
The predictive model was internally validated by
the bootstrap method, but further prospective studies
will be required to conﬁrm its external validity.
Application of new imaging techniques and bio-
markers may improve the risk stratiﬁcation of pa-
tients with ATTR in further studies.
The risk prediction model proposed in this study
accurately estimated the individual risk of death after
liver transplantation for patients with familial trans-
thyretin amyloidosis. The identiﬁcation of high-risk
patients should prompt the choice of liver trans-
plantation with extreme caution, and alternate thera-
peutic strategies (e.g., combined heart and liver
transplantations, new antiamyloid treatments) should
be considered.*Vincent Algalarrondo, MD, PhD
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1203–12.Neglecting Enterococci
May Lead to a
Misinterpretation of the
Consequences of Last
Changes in Endocarditis
Prophylaxis American
Heart Association
GuidelinesWe read with interest the paper by Pant et al. (1) in a
recent issue of the Journal about the 2000 to 2011
trends of infective endocarditis (IE) in the United
States. A main conclusion is that the incidence of
streptococcal IE signiﬁcantly rose since 2007,
following the restriction of antibiotic prophylaxis of
IE in the American Heart Association (AHA) guidelines.
Streptococcal IE increased from 24.8% in 2000 to 27%
in 2011,with higher incidence in the 2007 to 2011 period
(2.22 cases per million population [1.64 to 2.80] vs.
0.85 cases per million population [0.50 to 1.20] in the
2000 to 2007 period) (1). The authors stated that their
results contrast with data from Duval et al. (2), who did
not report such an increase of streptococcal IE since the
guidelines were modiﬁed, because short follow-up
may preclude detection of this switch in the pattern
of streptococcal IE. They also claim that a steadyincrease in streptococcal IE has also been reported in
the United Kingdom since the National Institute for
Health and Care Excellence guidelines were changed
(3). However, U.K. guidelines not only limited indi-
cations for IE prophylaxis, but also completely stopped
them in 2008. Hence, comparisons between AHA and
National Institute for Health and Care Excellence
guidelines should be carefully made.
The major caveat of the contribution by Pant et al.
(1), however, is their neglect of enterococci. The
authors did not differentiate between enterococcal
and other streptococcal IE, pooling all together.
Enterococcal IE is a growing entity worldwide, espe-
cially in the United States, due to an aging population
with numerous comorbidities acquiring the infection
in the health care setting (4). Consequently,we suspect
that the increase of overall streptococcal IE is not
related to rising viridans group IE cases due to failing
AHA guidelines, but rather to an increase of entero-
coccal IE hidden in the work of Pant et al. (1). All
physicians must be aware of the “enterococcal
menace” and not get distracted with crying wolves.Juan M. Pericas, MD
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